NYSE:AVNS Avanos Medical Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Avanos Medical Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $34.32 +1.10 (+3.31 %) (As of 09/25/2020 12:00 AM ET) Add Compare Share Today's Range$32.91Now: $34.32▼$34.4050-Day Range$30.87MA: $32.29▼$33.9452-Week Range$19.46Now: $34.32▼$48.07Volume229,525 shsAverage Volume352,521 shsMarket Capitalization$1.64 billionP/E RatioN/ADividend YieldN/ABeta1.07 ProfileAnalyst RatingsChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesOptions ChainShort InterestSocial Media Avanos Medical, Inc. operates as a medical technology company that focuses on delivering medical device solutions to improve patients' quality of life worldwide. It provides a portfolio of products focuses on respiratory and digestive health; pain management solutions; and minimally invasive interventional pain therapies, closed airway suction systems, and enteral feeding tubes. The company also offers Game Read, a product for pain management and rehabilitation of patients recovering from orthopedic surgery or sports-related injuries; GRPro 2.1, a cold and compression therapy system; Med4Elite, a multi-modality therapy unit; ATX Wraps; and various product accessories. In addition, it sells its products under the ON-Q, COOLIEF, MICROCUFF, MIC-KEY, HOMEPUMP, CORTRAK, and GAME READY brand names. The company markets its products directly to hospitals and other healthcare providers, as well as through third-party distribution channels. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.Read More Beat the Market (BTM) Rank™ 1.1 Analyst's Opinion Consensus RatingAvanos Medical has received a consensus rating of Hold. The company's average rating score is 2.17, and is based on 2 buy ratings, 3 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $33.20, Avanos Medical has a forecasted downside of 3.3% from its current price of $34.32.Amount of Analyst CoverageAvanos Medical has only been the subject of 1 research reports in the past 90 days. Previous Next 2.1 Community Rank Outperform VotesAvanos Medical has received 62 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAvanos Medical has received 85 “underperform” votes. (Add your “underperform” vote.)Community SentimentAvanos Medical has received 57.82% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Avanos Medical and other stocks. Vote “Outperform” if you believe AVNS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AVNS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAvanos Medical does not currently pay a dividend.Dividend GrowthAvanos Medical does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Avanos Medical insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.51% of the stock of Avanos Medical is held by insiders.Percentage Held by Institutions95.44% of the stock of Avanos Medical is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Avanos Medical are expected to grow by 74.19% in the coming year, from $0.62 to $1.08 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Avanos Medical is -98.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Avanos Medical is -98.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioAvanos Medical has a PEG Ratio of 8.60. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioAvanos Medical has a P/B Ratio of 1.30. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 1.1Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.21 out of 5 stars Industry, Sector and Symbol Stock Exchange NYSE Industry Surgical appliances & supplies Sub-IndustryN/A SectorMedical Current SymbolNYSE:AVNS Previous Symbol CUSIPN/A CIKN/A Webavanos.com Phone844-428-2667Debt Debt-to-Equity Ratio0.20 Current Ratio2.94 Quick Ratio1.95Price-To-Earnings Trailing P/E RatioN/A Forward P/E Ratio55.35 P/E Growth8.6 Sales & Book Value Annual Sales$697.60 million Price / Sales2.35 Cash Flow$1.88 per share Price / Cash Flow18.30 Book Value$26.40 per share Price / Book1.30Profitability EPS (Most Recent Fiscal Year)$1.07 Net Income$-45,900,000.00 Net Margins-2.40% Return on Equity3.52% Return on Assets2.50%Miscellaneous Employees4,700 Outstanding Shares47,832,000Market Cap$1.64 billion Next Earnings Date11/3/2020 (Estimated) OptionableOptionable $34.32 +1.10 (+3.31 %) (As of 09/25/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive AVNS News and Ratings via Email Sign-up to receive the latest news and ratings for AVNS and its competitors with MarketBeat's FREE daily newsletter. Avanos Medical (NYSE:AVNS) Frequently Asked Questions How has Avanos Medical's stock price been impacted by Coronavirus (COVID-19)? Avanos Medical's stock was trading at $29.01 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, AVNS shares have increased by 18.3% and is now trading at $34.32. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Avanos Medical? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avanos Medical in the last year. There are currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Avanos Medical. When is Avanos Medical's next earnings date? Avanos Medical is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020. View our earnings forecast for Avanos Medical. How were Avanos Medical's earnings last quarter? Avanos Medical Inc (NYSE:AVNS) announced its quarterly earnings data on Tuesday, August, 4th. The company reported $0.13 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.10) by $0.23. The firm earned $163.70 million during the quarter, compared to analysts' expectations of $147.90 million. Avanos Medical had a negative net margin of 2.40% and a positive return on equity of 3.52%. The business's revenue was down 4.9% compared to the same quarter last year. During the same quarter last year, the company posted $0.28 EPS. View Avanos Medical's earnings history. What price target have analysts set for AVNS? 6 Wall Street analysts have issued 1 year price objectives for Avanos Medical's stock. Their forecasts range from $30.00 to $43.00. On average, they anticipate Avanos Medical's share price to reach $33.20 in the next twelve months. This suggests that the stock has a possible downside of 3.3%. View analysts' price targets for Avanos Medical. Are investors shorting Avanos Medical? Avanos Medical saw a decline in short interest during the month of August. As of August 14th, there was short interest totaling 2,010,000 shares, a decline of 16.3% from the July 30th total of 2,400,000 shares. Based on an average trading volume of 292,800 shares, the days-to-cover ratio is currently 6.9 days. Approximately 4.3% of the company's shares are sold short. View Avanos Medical's Short Interest. Who are some of Avanos Medical's key competitors? Some companies that are related to Avanos Medical include Wound Management Technologies (WNDM), MSA Safety (MSA), Wright Medical Group (WMGI), Inogen (INGN), Establishment Labs (ESTA), Invacare (IVC), RTI Surgical (RTIX), Alpha Pro Tech (APT), Sientra (SIEN), Lakeland Industries (LAKE), Milestone Scientific (MLSS), ConforMIS (CFMS), COLLPLANT HOLDI/S (CLGN), Histogenics (HSGX) and Allied Healthcare Products (AHPI). View all competitors. What other stocks do shareholders of Avanos Medical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Avanos Medical investors own include Kimberly Clark (KMB), CVS Health (CVS), Honeywell International (HON), Pfizer (PFE), Procter & Gamble (PG), Johnson & Johnson (JNJ), AT&T (T), Abbott Laboratories (ABT), Alibaba Group (BABA) and NVIDIA (NVDA). Who are Avanos Medical's key executives? Avanos Medical's management team includes the following people: Mr. Joseph F. Woody, CEO & Director (Age 53)Mr. John W. Wesley, Sr. VP of Legal & Gov. Relations (Age 60)Mr. John R. Tushar, Pres of Global Franchises (Age 57)Mr. Arjun Ranjan Sarker, Sr. VP of International (Age 53)Mr. Warren J. MacHan, Sr. VP of Bus. Strategy & Interim CFO (Age 53) What is Avanos Medical's stock symbol? Avanos Medical trades on the New York Stock Exchange (NYSE) under the ticker symbol "AVNS." Who are Avanos Medical's major shareholders? Avanos Medical's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (9.37%), Paradice Investment Management LLC (5.55%), Victory Capital Management Inc. (4.08%), Macquarie Group Ltd. (3.49%), Goldman Sachs Group Inc. (3.32%) and Bank of New York Mellon Corp (1.18%). Company insiders that own Avanos Medical stock include Gary Blackford, John W Wesley, Joseph Fralin Woody and Steven E Voskuil. View institutional ownership trends for Avanos Medical. Which institutional investors are selling Avanos Medical stock? AVNS stock was sold by a variety of institutional investors in the last quarter, including Cove Street Capital LLC, Vanguard Group Inc., Advisor Group Holdings Inc., Confluence Investment Management LLC, Prudential Financial Inc., Oppenheimer Asset Management Inc., Russell Investments Group Ltd., and Charles Schwab Investment Management Inc.. View insider buying and selling activity for Avanos Medical. Which institutional investors are buying Avanos Medical stock? AVNS stock was purchased by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Neuberger Berman Group LLC, Goldman Sachs Group Inc., Macquarie Group Ltd., Paradice Investment Management LLC, Schonfeld Strategic Advisors LLC, Marshall Wace LLP, and Phocas Financial Corp.. Company insiders that have bought Avanos Medical stock in the last two years include Gary Blackford, John W Wesley, Joseph Fralin Woody, and Steven E Voskuil. View insider buying and selling activity for Avanos Medical. How do I buy shares of Avanos Medical? Shares of AVNS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Avanos Medical's stock price today? One share of AVNS stock can currently be purchased for approximately $34.32. How big of a company is Avanos Medical? Avanos Medical has a market capitalization of $1.64 billion and generates $697.60 million in revenue each year. The company earns $-45,900,000.00 in net income (profit) each year or $1.07 on an earnings per share basis. Avanos Medical employs 4,700 workers across the globe. What is Avanos Medical's official website? The official website for Avanos Medical is avanos.com. How can I contact Avanos Medical? Avanos Medical's mailing address is 5405 Windward Parkway Suite 100 South, Alpharetta GA, 30004. The company can be reached via phone at 844-428-2667 or via email at [email protected] This page was last updated on 9/26/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
